What was the primary driver for the increase in net sales for the second quarter of 2012?

The primary drivers for the 7% increase in net sales to $11.0 billion were a 6% rise in local prices and a 5% net increase from portfolio changes, largely due to the Danisco acquisition. This was partially offset by a 3% reduction from currency impact and a 1% decrease in volume.

What is the impact of the Imprelis® herbicide claims on the company's financials?

The Imprelis® herbicide claims resulted in a significant charge. For the second quarter of 2012, the Agriculture segment recorded a charge of $265 million related to these claims. Year-to-date, the charge was $315 million. While the company has recorded charges and is managing claims, it acknowledges that additional charges could arise, with a potential total range up to $575 million.

How did the Danisco acquisition impact the financial results?

The acquisition of Danisco had a notable positive impact on sales, particularly in the Industrial Biosciences and Nutrition & Health segments. For example, Industrial Biosciences sales increased by $177 million and Nutrition & Health sales increased by $399 million in the second quarter of 2012, largely due to the acquisition benefit.

What is the company's outlook regarding liquidity and financial resources?

DuPont believes its ability to generate cash from operations and access to capital markets is adequate to meet its financial needs. The company maintains a strong financial position, benefits from significant unused credit lines, and aims to balance returning cash to shareholders with investing for growth.

CTA-PB/CTA-PA 10-Q Quarterly Report Q2 FY2012

Summary

E. I. du Pont de Nemours and Company (DuPont) reported net sales of $11.0 billion for the second quarter of 2012, a 7% increase year-over-year, driven by higher prices and portfolio changes, primarily the Danisco acquisition. Despite a slight dip in overall volume, sales in developing markets showed strong growth of 11%. Net income attributable to DuPont was $1.179 billion, resulting in diluted earnings per share of $1.25, a marginal decrease from $1.29 in the prior year's second quarter. The company continues to focus on its strategy of leveraging science and technology to address global challenges, with significant investments in R&D and ongoing productivity improvements.

Financial Highlights

51 data points

Beta

Revenue

$9.92B

0.4% Gross Margin

Net Income

$1.18B

0.1% Net Margin

EPS (Diluted)

$1.23

Total Assets

$50.03B

Cash & Equivalents

$3.51B

Free Cash Flow

$365.00M

Financial Statements

Beta

Revenue	$9.92B
Cost of Revenue	$5.84B
Gross Profit	$4.07B
R&D Expenses	$533.00M
SG&A Expenses	$972.00M
Operating Expenses	$8.71B
Operating Income	$1.96B
Interest Expense	$117.00M
Net Income	$1.18B
EPS (Basic)	$1.24
EPS (Diluted)	$1.23
Shares Outstanding (Basic)	934.06M
Shares Outstanding (Diluted)	942.83M

Key Highlights

1Net sales increased by 7% to $11.0 billion in Q2 2012 compared to $10.3 billion in Q2 2011, driven by price increases and portfolio changes (Danisco acquisition).
2Sales in developing markets grew by 11% in Q2 2012, indicating successful expansion in key growth regions.
3Net income attributable to DuPont was $1.179 billion for Q2 2012, a slight decrease from $1.218 billion in Q2 2011.
4Diluted earnings per share (EPS) were $1.25 for Q2 2012, down from $1.29 in the prior year's quarter.
5The company recorded a significant charge of $265 million in Q2 2012 related to Imprelis® herbicide claims, impacting the Agriculture segment's profitability.
6Inventories decreased to $6.011 billion at the end of Q2 2012 from $7.195 billion at the end of 2011, reflecting improved inventory management.
7DuPont continues to return capital to shareholders, with dividends paid to stockholders of $788 million in the first six months of 2012.

EIDP, Inc. Quarterly Report for Q2 Ended Jun 30, 2012

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions